The N-terminal Tetrapeptide of Neutrophil Proteinase 3 Causes S-phase Arrest in Granulopoietic Progenitors.

Stefan Sköld, Bodil Rosberg and Tor Olofsson
Division of Hematology & Transfusion Medicine, Department of Laboratory Medicine, Biomedical Center, Lund University, Lund, Sweden

Objective: Secreted enzymatically inactive proforms of hematopoietic serine proteases proteinase 3 (PR3), azurocidin, and granzymes A, B, H, K, and M, are able to reduce the fraction of granulopoietic progenitors (CFU-GM) in S-phase, whereas human leukocyte elastase (HLE) and cathepsin G lack this ability. The objective of the present study was to map the specific sequence(s) of PR3 and other hematopoietic serine proteases responsible for the downmodulation of S-phase.

Methods: Synthetic peptides corresponding to N-terminal sequences of PR3, purified recombinant PR3 and HLE, as well as hybrid proteins constructed by interchanging the N-terminal regions of PR3 and HLE, thus creating PR3/HLE and HLE/PR3, respectively, were tested for their ability to reduce the fraction of human marrow CFU-GM killed by cytosine arabinoside. In addition, we measured the effect of synthetic peptides on bromodeoxyuridine (BrdU) incorporation in common myeloid progenitors (CMP) and granulocyte/macrophage progenitors (GMP) isolated by cell sorting.

Results: The common N-terminal motif of PR3 and other serine proteases, i.e. IVGG or IIGG, downmodulate the S-phase of CFU-GM at 40-80 nM concentration. Tetrapeptide IVGG, but not IVGR, significantly reduces BrdU-incorporation in GMP within the CD34+ population. When the N-terminal of HLE is presented by the HLE/PR3 hybrid protein it is fully active.

Conclusion: These findings demonstrate that the downmodulatory effect on CFU-GM in S-phase is an S-phase arrest mediated by the first four N-terminal amino acids of PR3, and also suggest that this activity is dependent on the configuration of the proform providing the correct presentation of this N-terminal motif.

INTRODUCTION

Proteinase 3 (PR3), human leukocyte elastase (HLE), cathepsin G and azurocidin are stored in the azurophil granules of the mature neutrophil (1,2). They belong to the hematopoietic serine protease superfamily which also include granzymes A, B, H, K, and M in cytotoxic T-cells/NK-cells (3), and mast cell chymase (4). They all have a high degree of sequence homology, and share the same principal processing, but the individual proteases also seem to be subjected to subtle differences in this processing (1,5-7). They are synthesized as pre-proenzymes with a signal sequence which is cleaved off immediately after translation/insertion into ER, and an N-terminal dipeptide, which is cleaved off during processing to give an active enzyme stored in the azurophil granules (1,5). It is generally believed that when the dipeptide is cleaved off, the new N-terminal of the mature form is turned into the molecule and becomes hidden, at the same time changing the conformation of the protein and making it enzymatically active (8,9). However, a minor portion escapes processing and granule storage, and is instead secreted as proforms with varying length of the propeptide (10). We have identified secreted pro-PR3 as a downregulator of CFU-GM in S-phase (10), and could ascribe the S-phase downregulatory effect almost exclusively to the di-dipeptide form (11); thus the effect is not dependent on enzymatic activity. The same S-phase downregulatory effect could also be shown for azurocidin and granzymes A, B, H, K and M (11). On the contrary, HLE and cathepsin G was shown to lack S-phase downregulatory effect (10,11). Taken
together, these findings suggested that the effect on CFU-GM in S-phase is dependent on N-terminal structures or amino acid motifs that are unique to the proforms of PR3, azurocidin and granzymes, or which are not exposed by the mature forms, respectively.

In the present study we wanted to define the structural determinants of PR3 responsible for S-phase downmodulation, and now demonstrate that the N-terminal tetrapeptide IVGG of mature PR3, or the corresponding IIGG in other serine proteases, have full ability to downmodulate the S-phase of CFU-GM. However, presence of this tetrapeptide motif does not in itself suffice for activity as demonstrated by the inactive proforms of human leukocyte elastase (HLE) or cathepsin G (11), but a HLE/PR3 hybrid protein gained activity demonstrating that the HLE N-terminal can exert activity when presented by PR3. In addition, we demonstrate that the mechanism of S-phase downmodulation is an arrest in S-phase as evidenced by a reduced incorporation of the thymidine analog bromodeoxyuridine (BrdU).

MATERIAL AND METHODS

Synthetic peptides and cytokines
The following peptides derived from PR3 were synthesized and analyzed by HPLC and mass spectrometry (BioMolecular Resource Facility, University of Lund): peptide#1: AARAAEIVGGHEA (-6 to +7), peptide#2: AEIVGGHEAQPH (-2 to +10), peptide#3: IVGGHEAQPH (+1 to +10), peptide#4: GAARAAE (-7 to-1), and peptide#5: GGTLIHPSFVLT (+30 to +41), with the N-terminal isoleucine in mature PR3 as number +1. Synthetic peptides corresponding to N-terminal amino acids +1 to +10 of other hematopoietic serine proteases were also synthesized: HLE (IVGGRRARPH), cathepsin G (IIGGRESRPH), azurocidin (IVGGRARPR), granzyme B (IIGGHEAKPH), and peptide PR3(Q8K) (IVGGHEAKPH), where glutamin is exchanged by lysine as in granzyme B at the same position.

In addition, the tetrapeptides IVGG (+1 to +4 of PR3, azurocidin, and HLE), IIGG (+1 to +4 of cathepsin G, and granzymes A, B, H, K, and M), and IVGR were synthesized and tested for activity. Peptides were dissolved in water at 10mM and stored frozen and diluted in McCoy’s medium with 1% FCS immediately before testing for effect on CFU-GM in S-phase or BrdU-incorporation (see below). Tetrapeptide AcSDKP (Innovagen AB, Lund, Sweden) was dissolved in IMDM with 1% FSC and stored at −80°C as 1 mM stock solution. Recombinant human macrophage inflammatory protein (hMIP-1α), and transforming growth factor (hTGF-β) were purchased from Stem Cell Technologies (Vancouver, BC, Canada).

Recombinant human leukocyte elastase with predetermined N-terminals
Recombinant HLE with either an N-terminal di-propeptide (HLE/di+) or no propeptide (HLE/mature) was produced mainly as described (11). Briefly, PCR primers were designed with EcoR1 and Xho1 sites to allow insertion of constructs into the pCEP-Pu2 vector for further transfection to the 293EBNA1 cell line (12), and sequences for a 6xHis-tag and an Enterokinase recognition site to allow purification on Ni-NTA-columns and cleavage by Enterokinase. As template was used a cDNA for human leukocyte elastase in the pCEP4 vector (13), and the following primers: 5’-GAC TTC GAA TTC CAC CAC CAC CAC CAC CAC GAC GAC GAC GAC GAC GAC GAC GAC GAC GAC AAG ATT GTG GGG GGC CGG CGA GC-3’ (upstream primer for HLE/mature), 5’-GAC TTC GAA TTC CAC CAC CAC CAC CAC CAC GAC GAC GAC GAC GAC GAC GAC GAC GAC GAC AAG TCG GAG ATT GTG GGG GGC CGG CGA GC-3’ (upstream primer for HLE/di+), and 5’-GAC TTC CTC GAG TCA GTG GGT CCT GCT GGC C-3’ (downstream primer for both; EcoR1 and Xho1 enzyme restriction sites underlined, sequences for 6xHis tag and enterokinase recognition site in italics, stop codon in bold).

Recombinant PR3/HLE hybrids
A two-step PCR was utilized for a reciprocal exchange of the first sixteen N-terminal amino acid residues of the di-propeptide forms of PR3 and HLE, i.e the two residues of the di-propeptide and the first fourteen residues of the mature sequence. For each construct pCEP-Pu2/PR3/di+ (11) and pCEP-Pu2/HLE/di+ (as described above) were used as cDNA templates. For construction of HLE/PR3 two parallel reactions were run; reaction α: upstream primer 5’-CCT GCC TGC CAC TGA GGG TTC-3’ and downstream primer 5’-CCG CAT CTG CAG GGA GCC CAT GAA GGG CGA CGA C-3’ with pCEP-Pu2/HLE/di+ as template, and reaction β: upstream primer 5’-ATG GCC TCC
CTG CAG ATG CGG-3’ and downstream primer
5´-GAC TTC CTC GAG
CGC TGT GGG AGG
GGC GGT TCA-3´ with pCEP-Pu2/PR3/di+ as
template (Xho1 restriction site underlined and stop
codon in bold). The products from reaction α and
reaction β were purified on agarose gels, and mixed
together to be run in a second step of PCR with
upstream primer from reaction α and downstream
primer from reaction β. In a corresponding fashion
PR3/HLE was constructed; reaction α with upstream
primer same as above, and downstream primer 5´-
GCG CAG CTG CAG GGA CAC CAT GTA GGG
CCG GGA GTG TGG C-3´ with pCEP-
Pu2/PR3/di+ as template; reaction β with upstream
primer 5´-ATG GTG TCC CTG CAG CTG CGC-3´
and downstream primer 5´-GAC TTC CTC GAG
TCA GTG GGT CCT GCT GGC C-3´ with pCEP-
Pu2/HLE/di+ as template. The final two proteinase
3/elastase hybrid constructs PR3/HLE and
HLE/PR3, respectively were cut out and ligated into
pCEP-Pu2 and transfected to the 293EBNA1 cell
line. DNA sequencing was performed to verify the
right sequence of the respective constructs.

By chance we detected a mutation in one of the
PR3/HLE constructs where glycine number four was
exchanged by an arginine, and this construct was
taken to transfection also and purification of the
recombinant dipeptide proform, named
PR3(G4R)/HLE.

**Transfection procedures for HEK293EBNA1 cells**

Wild type HEK293EBNA1 cells (12) were grown in
DMEM with 10%FCS, penicillin 50 IU/mL
streptomycin 50 Ug/mL and geneticin 250 µg/mL.
Lipofectin (Superfect, Qiagen GmbH, Germany)
was used according to the manufacturer’s protocol
for stable transfection of adherent cells. After
transfection, cells were grown 24-48 h in
DMEM/10%FCS/geneticin before passage and
addition of puromycin 0.5 µg/mL for selection of
transfected clones. At confluency, cells were washed
twice with PBS and medium was changed to serum-
free DMEM with ascorbate (50 µg/mL) for
production of recombinant protein. Every second
day conditioned medium (CM) was removed and
stored frozen until processing, and fresh medium
was added for another round of CM production for a
total of 3-4 harvests.

**Purification of recombinant proteins produced in
293EBNA1 cells**

Purification was performed mainly as described
(11). Briefly, serum-free CM were pooled, filtered
and adjusted to pH 7.8, 500 mM NaCl and 10 mM
imidazole, before incubation with ProBond Ni-NTA
resin (Invitrogen, Paisley, UK) at +4°C over night at
constant stirring. After washing recombinant protein
was eluted with 20 mM sodium-phosphate-buffer
pH 6.0, 500 mM NaCl, 150-300 mM imidazole,
before concentration and buffer exchange to EKMax
reaction buffer (50 mM Tris-HCl pH 8.0, 1 mM
CaCl2, 0.1% Tween-20). Concentrated pure
recombinant protein was then subjected to
enterokinase cleavage (EKMax™, 1U/µl; Invitrogen)
at room temperature over night. Purity
and size of cleaved protein was confirmed on SDS-
PAGE.

**S-phase analysis of CFU-GM**

This was done as previously described (10,11).
Briefly, human bone marrow mononuclear cells
from healthy donors (after informed consent and
approved by the Ethical Committe of the University
Hospital in Lund) were incubated in duplicates with
McCoy’s medium 1% FCS (control) and synthetic
peptides or purified recombinant proteins for 90 min
at 37°C. After 90 min 2 ug/mL cytosine arabinoside
(Cytosar, Pharmacia & Upjohn) was added to one of
the tubes in each pair and the incubation continued
for another 45 min to kill cells in S-phase. Cells
were then washed and cultured in agar in four
replicates with 20 ng/mL G-CSF (Neupogen, Roche)
and 20 ng/mL GM-CSF (Leucomax, Schering-
Plough) as colony-stimulating factors. CFU-GM
colonies of more than 50 cells were counted on day
11. The reduction in colony number after incubation
with cytosine arabinoside is a measure of the
number of CFU-GM in S-phase. Colony numbers
were always >100/dish. In some experiments
CD34+ cells were isolated by magnetic microbeads
(CD34 progenitor cell isolation kit; Miltenyi Biotec,
Bergisch Galdbach, Germany) and used as target
cells as described (10); the purity of the CD34+ cells
used in these experiments was more than 90%.

**Bromodeoxyuridine (BrdU) incorporation in
progenitor cells**

As another means of cell cycle analysis we
measured BrdU incorporation in progenitor cells
isolated by cell sorting. BrdU incorporation was
measured using the Absolute-S Kit (Phoenix Flow
Systems, San Diego, CA) and all steps were
performed as described by the manufacturer. Briefly,
human CD34+ marrow cells isolated by immunomagnetic beads (Miltenyi Biotec) were incubated with tetrapeptides IVGG or IVGR (inactive control) (80 nM) for 90 min at 37°C before addition of BrdU for another 20 min. Thereafter cells were washed twice in cold medium and labeled with monoclonal antibodies. The following combinations were used: CD45RA-PE/CD19-PerCP-Cy5.5/CD34-APC (without any FITC-labeled MoAb), CD19-FITC/CD123-PE/CD34-PerCP-Cy5.5/CD19-PerCP-Cy5.5/CD45RA-APC, and CD34-FITC/CD19-PerCP-Cy5.5/CD45RA-APC (all from BD Biosciences, San Jose, CA) and sorted on a FACS Aria cell sorter (BD Biosciences). CD34+/CD19- cells were sorted into CD45RA- and CD45RA+ subpopulations representing common myeloid progenitors (CMP) and granulocyte/macrophage progenitors (GMP), respectively (14). 100-200,000 cells of each population was collected into cold medium and directly taken to further processing with PhotoLyte Enhancer, fixation in ice-cold 70% (v/v) ethanol and storage at –20°C for at least 18 hours before proceeding with UV-light treatment (8 min), BrdU incorporation and staining with anti-BrdU-FITC antibody. After dilution in buffer containing PI (propidium iodide) and RNase, BrdU incorporation was measured by flow cytometry (FACScan, BD Biosciences) within 30 min. Cell debris and doublets were excluded from analysis by gating on PI in a fluorescence area versus width dot plot. Cell cycle distribution based on the incorporation of PI was analyzed using ModFit LT software (Verity Software House, Topsham, ME).

RESULTS

Synthetic peptides of PR3 and other serine proteases

Four different peptides corresponding to N-terminal sequences of PR3 were synthetically produced and taken to assay for CFU-GM in S-phase. Peptides #1, #2, and #3, downmodulated the S-phase fraction of CFU-GM at 20 nM (Fig.1). Downmodulation was dose-dependent over a range of 0.8, 4, 20, and 100 nM, with a tendency towards a biphasic response with a slightly weaker or equal inhibitory activity at 100 nM as at 20 nM (data not shown). Peptides #1-#3 all contain the initial seven amino acids of the mature form of PR3. Peptide #4, which represents the seven amino acids of the propeptide preceding the isoleucine of mature PR3, and peptide #5, corresponding to amino acids 30-41 of mature PR3 were both inactive (0.8-100 nM). These findings show that the propeptide amino acids are dispensable for activity and that capacity to downmodulate CFU-GM in S-phase is exerted by peptides which share the common IVGGHEA motif of mature PR3.

![Fig.1. Reduction of the fraction of CFU-GM in S-phase by synthetic peptides corresponding to different parts of the N-terminal region of PR3 (peptides #1-#4) and an internal sequence corresponding to amino acids 30-41 (peptide #5). The peptide sequences are shown within brackets. Peptides were tested at 20 nM final concentration. Results are mean values of 3-4 experiments and the bars show SD; * denotes significant difference from the control (p<0.01).]

Since the N-terminal sequences of all hematopoietic serine proteases are similar synthetic peptides corresponding to the first 10 amino acids of mature azurocidin, HLE, cathepsin G and granzyme B, respectively, were tested for activity in comparison with the PR3 peptide equivalent, i.e. peptide #3. However, only PR3 peptide #3 was able to downmodulate the S-phase of CFU-GM (Fig.2). Interestingly, if glutamin in position eight is substituted with lysine (Q8K), as in granzyme B, the resulting peptide becomes inactive just as the granzyme B peptide. These results demonstrate that although the peptides share the common IVGGHEA motif the composition of the following six amino acids affects the activity.
Comparison of the S-phase downmodulatory effect of synthetic peptides corresponding to the first ten amino acids of mature PR3, azurocidin (Azu), human leukocyte elastase (HLE), cathepsin G (CathG), granzyme B (GrzB), and a mutated form of the PR3 peptide (PR3/Q8K). The peptide sequences are shown within brackets. The peptides were tested at 20 and 100 nM concentration and the results from 20 nM are shown; the higher concentration did not change the overall results. Results are mean values of three experiments and the bars show SD; * denotes significant difference from the control (p<0.01). PR3(Q8K) is significantly different from unmutated PR3 (p<0.01).

In the next set of experiments we tested whether the common tetrapeptide motifs IVGG/IIGG by themselves were active. As shown in Fig.3 both tetrapeptides significantly downmodulated the S-phase fraction in a dose-dependent manner with maximum effect at 40-80 nM, which is approximately 10-20 times higher concentration than required for native pro-PR3 (10). Tetrapeptide IVGR was inactive.

Interchange of N-terminal sequences between PR3 and HLE

The proform of HLE does not exhibit S-phase downmodulatory activity despite the presence of the active tetrapeptide motif IVGG (11). To test the hypothesis that the N-terminal of HLE is incorrectly presented to execute this activity, we exchanged the N-terminal region of PR3 with the N-terminal region of HLE including the di-propeptide (HLE/PR3) (Fig.4). In addition, we produced the reversed transfer and exchanged the N-terminal of HLE with the N-terminal region of PR3 (PR3/HLE) (Fig.4) to test whether the N-terminal of PR3 becomes inactive when presented by HLE. If the hypothesis was correct the HLE/PR3 fusion protein would be active, which turned out to be the case as shown in Fig.5. This finding demonstrates that the N-terminal of HLE gain activity if coupled to the C-terminal part of PR3. However, the reciprocal N-terminal exchange, i.e. PR3/HLE, also was active (Fig.5) but less potent than the native pro-PR3. The mutant form of PR3/HLE, however, with an exchange of glycine number four by arginine, i.e. PR3(G4R)/HLE, lost all activity, which underlines the importance of the IVGG/IIGG motif. This was further substantiated by the observation that when the peptide IVGG is changed to IVGR it becomes totally inactive (Fig.3).

AcSDKP, MIP-1α and TGF-β

For comparison some other known inhibitors of hematopoietic stem and progenitor cell proliferation were tested in the same way as PR3 derived peptides. AcSDKP at 50 or 100 ng/mL did not reduce the fraction of CFU-GM killed by cytosine arabinoside (control: 34,1% ± 4 ; AcSDKP 50 ng/mL: 36,6% ± 1,0; AcSDKP 100 ng/mL: 33,4% ± 2,7; n=4). MIP-1α at 50 and 100 ng/mL was also without effect (50 ng/mL: 35,5% ± 4,0; 100 ng/mL: 35,7% ± 2,6; n=4), just as TGF-β at 25 ng/mL (36,6% ± 7,1; n=3).
Fig. 4. Panel A. Schematic outline of PR3, HLE, and the hybrids produced in recombinant form. Panel B. The electrophoretic pattern on SDS-PAGE and silver staining of the purified fusion proteins HLE/PR3, PR3/HLE, and the mutated PR3(G4R)/HLE, respectively, before and after removal of the His-tag by enterokinase (EK) cleavage. The hybrids containing a HLE C-terminal show two bands, which is identical with the electrophoretic pattern for recombinant wild type HLE (data not shown). This two-band pattern is probably due to differences in glycosylation or incomplete C-terminal processing that removes the 20 amino acid C-terminal prodomain, which is not necessary for enzymatic activity nor for targeting to granules (13). Both components contain the His-tag as evidenced by the shift in mobility after enterokinase treatment.

Fig. 5. Reduction of the S-phase fraction of CFU-GM by recombinant dipeptide proforms of wild type PR3 and HLE, the two reciprocal N-terminal switches HLE/PR3 and PR3/HLE, and the mutant PR3(G4R)/HLE, respectively. Results are mean values of three experiments and the bars show SD. * denotes significant difference from the control (p<0.05).

PR3 peptides act on purified CD34+ cells
Previously we have shown that the proform of PR3 acts directly on target cells within the CD34+ hematopoietic progenitor population (10). To test whether this is true also for the inhibitory PR3 peptides, peptides #1 -3 and the tetrapeptides IVGG/IIGG were tested for activity towards purified human marrow CD34+ progenitor cells. As shown in Fig.6 the peptides also were active towards purified CD34+ cells suggesting that they act directly on the progenitor cells rather than via indirect mechanisms.

Fig. 6. Peptides act directly on CD34+ cells. Isolated bone marrow CD34+ cells were used as target cells for peptides #1-3 (20 nM) and tetrapeptides IVGG and IIGG (80 nM). Columns show mean values and bars SD; controls (n=6), peptide #1 (n=3), peptide #2 (n=2), peptide #3 (n=4), IVGG (n=2), and IIGG (n=2). For statistical testing peptides #1-3, and IVGG/IIVV, respectively, were grouped together; * denotes significant difference from the controls (peptides #1-3: p-value 0.001, IVGG/IIGG: p-value 0.011).

PR3 peptides inhibit BrdU incorporation in granulocyte/macrophage progenitor cells (GMP)
Fig. 7 shows the isolation of CMP and GMP populations by cell sorting according to the definitions proposed by Manz et al (14). CD19+ cells were excluded as the major non-myeloid component of marrow CD34+ cells and CD34+/CD19- cells were divided into CD123lo/CD45RA- (CMP) and CD123lo/CD45RA+ (GMP), respectively, or CD45RA- and CD45RA+ in those experiments. CD123 was not included. However, the important discriminator between CMP and GMP is CD45RA. An example of BrdU incorporation by GMP is shown in Fig. 7 (lower part). The collective data of nine separate marrow samples demonstrated that
IVGG significantly inhibited the BrdU incorporation of GMP but hardly so of CMP, whereas full-length proPR3 inhibited BrdU incorporation of both progenitor populations (Fig. 8). However, when the cell cycle distribution according to PI-labeling was analyzed no significant differences were observed between controls and IVGG-exposed cells (data not shown).

**DISCUSSION**

Previously we have shown that the capacity of PR3 to downmodulate the S-phase of granulopoietic progenitors is restricted to the dipeptide-containing proform, and the same is true for azurocidin and granzyme B, whereas the mature enzymatically active forms lack S-phase regulatory activity (11). In the proform conformation of hematopoietic serine proteases the N-terminal is exposed on the surface of the molecule as recently confirmed by the crystal structure of pro-granzyme K (15). Removal of the dipeptide results in conformational changes and the N-terminal is turned inwards and is no longer exposed on the surface of the mature protein (8,9). Therefore, we have argued that the activity towards granulopoietic progenitors probably is exerted by N-terminal structures. The initial tests of synthetic peptides derived from N-terminal sequences of PR3 proved that this assumption was correct and that the activity resided within the sequence IVGGHEA common to the active peptides. However, the finding that the N-terminal decapptide of granzyme B was inactive was unsuspected in view of the fact that the full length pro-granzyme B is active. The observation that a single amino acid exchange in the PR3 decapptide (Q8K) abrogated the activity, suggested that the activity of the decapptides are influenced by net charge of the molecules. For instance, the inactive PR3(Q8K) peptide gains another basic amino acid making its net charge equal to the inactive granzyme B and cathepsin G decapptides, respectively, which supports this interpretation.

Next we suspected that the activity may be executed by the most N-terminal amino acids IVGG. These are the first four amino acids of mature PR3, azurocidin, and elastase, whereas cathepsin G and all the granzymes start with IIGG. In fact, both these tetrapeptides were active towards granulopoietic progenitors, and a single amino acid change from IVGG to IVGR totally abrogated the effect. Thus it is evident that the IVGG/IIGG motif mediates the S-
phase downmodulatory signal. However, it is also evident that the presence of this amino acid motif is not in itself enough for activity when it comes to the native proteases. Presentation or conformation of the N-terminal region is also important for activity as demonstrated by switching the N-terminals between PR3 and HLE. The HLE/PR3 fusion protein demonstrated that the HLE N-terminal gains activity when fused to PR3 and suggests that the presentation of the N-terminal of HLE is different from that of wild type HLE. On the other hand, the PR3/HLE fusion protein retained activity, but was less potent than wild type pro-PR3 or HLE/PR3, which could be explained by a less efficient presentation of the N-terminal of PR3 by HLE than by wild type PR3. In both cases, the fusion proteins demonstrate the importance of the overall conformation of the fusion proteins as well as the wild type proforms for the activity towards CFU-GM. However, the IVGG/IIGG motif must be intact as demonstrated by the mutated PR3(G4R)/HLE which had no activity, as well as the inactive tetrapeptide IVGR.

The peptides were active towards purified CD34+ marrow cells and furthermore, inhibited incorporation of BrdU in granulocyte/macrophage progenitors (GMP) without changing the cell cycle distribution, which taken together indicate that the peptides cause an arrest in S-phase. This observation explains the mechanism and rapid onset of the S-phase downmodulatory effect of pro-PR3 and the N-terminal peptides shown here. By arresting progenitor cells in S-phase pro-PR3 reduces not only incorporation of BrdU but also of cytosine arabinoside leading to reduced killing of cells in S-phase as measured in the colony assay.

Previously described inhibitors such as the tetrapeptide AcSDKP (acetyl-N-Ser-Asp-Lys-Pro) and chemokine MIP-1α inhibits the cycling of normal progenitors (16-19) but did not reduce the killing of CFU-GM by cytosine arabinoside in the short term assay used in the present investigation. TGF-β, another inhibitor of progenitor cell growth (18, 20), was also without effect. These inhibitors generally require longer incubation periods than used in the present study to show inhibition, and the results presented here suggest that the PR3 derived peptides act by mechanisms different from those of AcSDKP, MIP-1α and TGF-β, respectively.

Acknowledgement.
This study was supported by the Swedish Cancer Foundation, Ingabritt and Arne Lundberg’s Research Foundation, Georg Danielsson’s Foundation, Alfred Osterlund’s Foundation, John Persson’s Foundation, and the Research Funds of the University Hospital in Lund.

References
18. Cashman JD, Eaves CJ, Sarris AH, Eaves AC. MCP-1, not MIP-1α, is the endogenous chemokine that cooperates with TGF-β to inhibit the cycling of primitive normal but not leukemic (CML) progenitors in long-term human marrow cultures. Blood 1998;92:2338-2344.